Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors

Gene Therapy

Volumn 12, Issue 7, 2005, Pages 588-596

  Rueger, M A ^a   Winkeler, A ^a   Miletic, H ^a   Kaestle, C ^a   Richter, R ^a   Schneider, G ^a   Hilker, R ^a   Heneka, M T ^a   Ernestus, R I ^a   Hampl, J A ^a   Fraefel, C ^a   Jacobs, A H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

HSV 1 amplicon vector; Primary cell culture

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; NECTIN 1; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

AMPLICON; ARTICLE; BRAIN METASTASIS; BRAIN TUMOR; CELL TYPE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; GLIOBLASTOMA; GLIOMA CELL; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MENINGIOMA; MOLECULAR MECHANICS; MONITORING; NEUROSURGERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; SAMPLING; STATISTICAL SIGNIFICANCE; TRANSGENE; TUMOR CELL CULTURE; TUMOR CELL LINE; VIRAL GENE DELIVERY SYSTEM; VIRUS CELL INTERACTION; VIRUS INFECTIVITY;

BRAIN NEOPLASMS; CELL ADHESION MOLECULES; CELL PROLIFERATION; GENE EXPRESSION; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; NEOPLASM PROTEINS; RECEPTORS, VIRUS; TIME FACTORS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

HERPES; HUMAN HERPESVIRUS 1;

EID: 20144386940     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302462     Document Type: Article

References (59)

1. Kleihues P, Cavenee WK. Pathology and Genetics of Tumours of the Nervous System (WHO). International Agency for Research on Cancer, IARC Press: Lyon, 2000.
2. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW. Histopathology, classification, and grading of gliomas. Glia 1995; 15: 211-221.
3. Preston-Martin S. Epidemiology of gliomas. In: Berger MS, Wilson CD (eds). The Gliomas. Saunders: Philadelphia, 1999, pp 2-11.
4. Tatter SB, Harsh GR. Current treatment modalities for brain tumors. In: Chiocca EA, Breakefield XO (eds). Gene Therapy for Neurological Disorders and Brain Tumors. Humana Press: Totowa, NJ, 1998, pp 161-189.
5. Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
6. Heise C et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2003; 6: 1134-1139.
7. Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis. Neoplasia 1999; 1: 387-401.
8. Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications. Neoplasia 1999; 1: 402-416.
9. Kramm CM et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 1997; 8: 2057-2068.
10. Markert JM et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Therapy 2000; 7: 867-874.
11. Martuza RL et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856.
12. Rampling R et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Therapy 2000; 7 859-866.
13. Constantini LC et al. Gene transfer to the nigrostriatal system by hybrid HSV/AAV amplicon vectors. Hum Gene Ther 1999; 10: 2481-2494.
14. Fraefel C et al. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 1996; 70: 7190-7197.
15. Jacobs A et al. Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes. Hum Gene Ther 2003; 14 277-297.
16. Aboody-Guterman KS et al. Green fluorescent protein as a reporter for retrovirus and helper virus-free HSV-1 amplicon vector-mediated gene transfer into neural cells in culture and in vivo. Neuroreport 1997; 8: 3801-3808.
17. Maleniak TC, Darling JL, Lowenstein PR, Castro MG. Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU. Cancer Gene Ther 2001; 8: 589-598.
18. Davidson BL, Breakefield XO. Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci 2003; 4: 353-364.
19. Lasner TM et al. Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS. J Neuropathol Exp Neurol 1996; 55: 1259-1269.
20. Liu BL et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy 2003; 10: 292-303.
21. Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1 938-943.
22. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998; 9: 2177-2185.
23. Papanastassiou V et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Therapy 2002; 9: 398-406.
24. Chahlavi A et al. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Therapy 1999; 6: 1751-1758.
25. Delman KA et al. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther 2000; 11: 2465-2472.
26. Lambright ES et al. Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model. Mol Ther 2000; 2: 387-393.
27. Goss JR et al. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Therapy 2001; 8: 551-556.
28. Hao S et al. HSV-mediated gene transfer of the glial cell-derived neurotrophic factor provides an antiallodynic effect on neuropathic pain. Mol Ther 2003; 8: 367-375.
29. Lim F et al. Generation of high-titer defective HSV-1 vectors using an IE 2 deletion mutant and quantitative study of expression in cultured cortical cells. Biotechniques 1996; 20 460-469.
30. Preston CM. Control of herpes simplex virus type 1 mRNA synthesis in cells infected with wild-type virus or the temperature-sensitive mutant tsK. J Virol 1979; 29: 275-284.
31. Pechan PA et al. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas. J Gene Med 1999; 1: 176-185.
32. Cunningham C, Davison AJ. A cosmid-based system for constructing mutants of herpes simplex virus type 1. Virology 1993; 197: 116-124.
33. Saeki Y et al. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 2001; 3: 591-601.
34. Saeki Y, Breakefield XO, Chiocca A. Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods Mol Med 2003; 76: 51-60.
35. Johnston KM et al. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum Gene Ther 1997; 8: 359-370.
36. Costantini LC, Fraefel C, Breakefield XO, Isacson O. Herpes simplex virus/adeno-associated virus hybrid vectors for gene transfer to neurons. Preparation and use. Methods Mol Med 2002; 69: 479.
37. Sandler VM et al. Modified herpes simplex virus delivery of enhanced GFP into central nervous system. J Neurosci Methods 2002; 121: 211-219.
38. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 1994; 54: 3963-3966.
39. Spear MA et al. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Therapy 2000; 7: 1051-1059.
40. Aghi M et al. Multimodal cancer treatment mediated by replicating oncolytic virus that delivers the oxazaphosphorine/ rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 1999; 59: 3861-3865.
41. Chase M, Chung RY, Chiocca A. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophophamide chemotherapy. Nat Biotechnol 1998; 16: 444-448.
42. Advani SJ et al. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Therapy 1998; 5: 160-165.
43. Pyles RB et al. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum Gene Ther 1997; 8 533-544.
44. Kaplitt MG et al. Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J Neuro-Oncol 1994; 19: 137-147.
45. Andreansky S et al. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 1997; 57: 1502-1509.
46. Hoshi M et al. Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: consequences for anti-cancer gene therapy. Cancer Gene Ther 2000; 7: 799-805.
47. Moriuchi S et al. Enhanced tumor cell killing in the presence of ganciclovir by herpessimplex virus type 1 vector-directed coexpression of human tumor necrosis factor-a and herpes simplex virus thymidine kinase. Cancer Res 1998; 58: 5731-5737.
48. Lam P et al. Dynamics of transgene expression in human glioblastoma cells mediated by herpes simplex virus/adeno-associated virus amplicon vectors. Hum Gene Ther 2002; 13: 2147-2159.
49. Jacobs A et al. Positron-emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res 2001; 61: 2983-2995.
50. Burton EA, Fink D, Glorioso JC. Gene delivery using herpes simplex virus vectors. DNA Cell Biol 2002; 21: 915-936.
51. Campadelli-Fiume G, Cocchi F, Menotti L, Lopez M. The novel receptors that mediate the entry of herpes simples viruses and animal alphaherpesviuses into cells. Rev Med Virol 2000; 10: 305-319.
52. Mata M, Zhang M, Hu X, Fink DJ. HveC (nectin-1) is expressed at high levels in sensory neurons, but not in motor neurons, of the rat peripheral nervous system. J Neurovirol 2001; 7: 476-480.
53. Darnell Jr JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
54. Rosenblum MG et al. Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2′,5′-oligoadenylate synthetase and protein kinase activity. J Interferon Res 1990; 10: 141-151.
55. Spear MA et al. HSV-1 amplicon peptide display vector. J Virol Methods 2002; 107: 71-79.
56. MacKie EA et al. Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours - evaluation of a potentially effective clinical therapy. Br J Cancer 1996; 74: 745-752.
57. Detta A et al. Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours. J Gene Med 2003; 5: 681-689.
58. Ichikawa T et al. MRI of transgene expression: correlation to therapeutic gene expression. Neoplasia 2002; 4 523-530.
59. Fraefel C et al. Gene transfer into hepatocytes mediated by helper virus free HSV/AAV hybrid vectors. Mol Med 1997; 3: 813-825.